Business Wire

New GSMA Report Highlights Integral Role of Mobile IoT Networks in 5G Future

Jaa

The GSMA today issued a new report, ‘NB-IoT and LTE-M in the 5G context’, highlighting the integral role that licensed Mobile IoT networks, such as NB-IoT and LTE-M, will play in the 5G future and, in particular, the development of ‘massive IoT’. Massive IoT is one of three principle 5G use cases, alongside critical communications and enhanced broadband, that will enable developments such as smart cities and industrial automation. NB-IoT and LTE-M will be fundamental to the development of massive IoT and in supporting and complementing 5G’s myriad use cases and applications. Leading operators including AT&T, Deutsche Telekom, KDDI, Orange and Vodafone are committed to deploying these networks as part of their future 5G massive IoT strategies.

“While people often associate 5G with super-fast mobile broadband speeds, it will also serve a variety of use cases often with diametrically opposed requirements such as low data rates and long battery life as with the case of Mobile IoT,” commented Alex Sinclair, Chief Technology Officer, GSMA. “Licensed NB-IoT and LTE-M networks are already delivering trusted connectivity today to millions of devices around the world, and these networks will continue to be a fundamental component of our 5G future ushering in an era of massive IoT.”

Mobile operators, in collaboration with global vendors and developers, are launching Mobile IoT networks today to support applications such as smart metering, smart logistics and smart environmental monitoring, but also as a core component of their long-term strategy and commitment to 5G IoT standards. Licensed Mobile IoT networks are standardised by 3GPP and are designed to support cellular IoT applications that are low cost, use low data rates, require long battery lives and often operate in remote and hard-to-reach locations such as industrial asset tracking, safety monitoring or water and gas metering. To date, 24 mobile operators have commercially launched 48 Mobile IoT networks worldwide across both NB-IoT and LTE-M technologies. According to GSMA Intelligence forecasts, by 2025 there will be 3.1 billion cellular IoT connections, including 1.8 billion licensed LPWA connections.

3GPP is set to complete Release 15 in June, which will include NB-IoT and LTE-M as 5G Mobile standards. 3GPP will also not include any additional LPWA requirements in its next release, meaning that NB-IoT and LTE-M will coexist with other 3GPP technologies and fulfil long-term 5G LPWA requirements. NB-IoT and LTE-M networks will deliver connectivity to billions of new devices and provide comprehensive IoT connectivity in the 5G era.

For more information on GSMA’s Mobile IoT Initiative and to download the report ‘NB-IoT and LTE-M in the 5G context’, please go to: https://www.gsma.com/iot/mobile-iot-5g-future/

-ENDS-

PARTNER QUOTES

AT&T
“Low-Power Wide-Area networks hold the key to global deployment of IoT devices and applications that will only grow with 5G,” said Chris Penrose, President, Internet of Things Solutions, AT&T. “Our investment in Massive IoT in the U.S. and Mexico marks another step forward on our path to 5G with 3GPP standardised technology and licensed spectrum.”

DEUTSCHE TELEKOM
“Deutsche Telekom fully supports GSMA’s statement of the integral role of Mobile IoT networks in the 5G future. Looking further, LPWA technologies such as NB-IoT have been paving the way for 5G and will be an important part of the 5G technologies – with its virtualised core networks already implemented at Deutsche Telekom, it is reality today for us,” said Dr. Ingo Hofacker, SVP, IOT, Deutsche Telekom.

KDDI
“The GSMA report clarifies the ambiguity in the relationship between LPWA and 5G by highlighting that the existing LPWA 3GPP technologies are set to coexist with other 3GPP 5G technologies and fulfil longterm LPWA requirements. For the age of IoT and 5G, KDDI will establish Open Labs to facilitate the rapid development of innovative services in Tokyo in the summer of 2018,” said Keiichi Mori, Managing Executive Officer, GM, IoT Business Development Division.

VODAFONE GROUP
Luke Ibbetson, Head of R&D for Vodafone Group and Chair of the GSMA NB-IoT Forum, said: “Vodafone pioneered the development of NB-IoT and already has networks in nine countries. We strongly believe that NB-IoT, the first 5G internet of things network, will be the foundation for a society where people and businesses are far more connected to and informed about the world around them.”

About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

Contact information

Media Contacts:
For the GSMA
Beau Bass
+44 79 7662 4962
beau.bass@webershandwick.com
or
GSMA Press Office
pressoffice@gsma.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45Tiedote

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10Tiedote

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30Tiedote

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme